

## **PEARLS**



Practical Evidence About Real Life Situations

Oral erythromycin may	oe effective in	treating the symp	-
toms of pityriasis rosea			

Clinical question	Are there any effective interventions to treat symptoms of pityriasis rosea?
Bottom line	Oral erythromycin may be effective in treating the rash and relieving the itch. There is inadequate evidence for the efficacy of most treatments (including liquorice root, local anaesthetics, penicillin, clarithromycin and oral steroids).
Caveat	Limitations of this review include the small number of trials identified (3), the small number of participants involved, the inadequate methodology of two of the studies, and finding only I small study (40 people) that reported the clinical benefits of oral erythromycin. However, the methodological quality of this study was judged to be good.
Context	Pityriasis rosea is a scaly rash that affects mainly young adults. It is relatively common, affecting about 170 out of every 100,000 people in the community each year. About 50 per cent of patients experience moderate to severe itch, but most people recover within 2 to 12 weeks.
Cochrane Systematic Review	Chuh AAT et al. Interventions for pityriasis rosea. Cochrane Database of Systematic Reviews 2007, Issue 2. Article

PEARLS No. 10, August 2007, written by Brian R McAvoy

PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners — developed by the Cochrane Primary Care Field, New Zealand Branch of the Australasian Cochrane Centre at the Department of General Practice and Primary Health Care, University of Auckland and funded by the New Zealand Guidelines Group. New Zealanders can access the Cochrane Library free via www.nzgg.org.nz

CD005068.pub2.

148 participants.

PEARLS provide guidance on whether a treatment is effective or ineffective. PEARLS are prepared as an educational resource and do not replace clinician judgement in the management of individual cases. View PEARLS online at: www.nzdoctor.co.nz; www.nzgg.org.nz; www.cochraneprimarycare.org





No. CD005068. DOI: 10.1002/14651858.

Note: This review contains 3 small trials and